Skip to main content

Advertisement

Table 1 Baseline characteristics of study participants

From: Influence of subcutaneous specific immunotherapy on drug costs in children sufferingfrom allergic asthma

Item SCIT Control p-value
Baseline characteristics including outliers (all randomizedpatients)
n 33 32  
Female proportion [n (%)] 11 (33.3%) 10 (31.2%) 0.534
Mean age in years [mean (SD)] 10.0 (3.1) 10.6 (2.9) 0.403
GINA level 2 [n (%)] 26 (78.8%) 26 (81.2%) 0.525
GINA level 3 [n (%)] 7 (21.2%) 6 (18.8%)
Mean peak flow in l/min [mean (SD)] 296 (101) 315 (91) 0.444
Mean annual costs for allergic-drugs before intervention onset in euro[mean (SD)] 434 (332) 296 (220) 0.130
Mean annual costs for non-allergic-drugs before intervention onset ineuro [mean (SD)] 51 (87) 50 (98) 0.571
Mean total annual drug costs before intervention onset in euro [mean(SD)] 485 (377) 345 (245) 0.083
Baseline characteristics without outliers (all analysedpatients)
n 28 31  
Female proportion [n (%)] 8 (28.6%) 10 (32.3%) 0.785
Mean age in years [mean (SD)] 10.4 (3.2) 10.8 (2.8) 0.628
GINA level 2 [n (%)] 21 (75.0%) 25 (80.6%) 0.417
GINA level 3 [n (%)] 7 (25.0%) 6 (19.4%)
Mean asthma level GINA [mean (SD)] 2.25 (0.441) 2.19 (0.402) 0.755
Mean peak flow in l/min [mean (SD)] 308 (105) 317 (91) 0.727
Mean annual costs for allergic-drugs before intervention onset in euro[mean (SD)] 315 (180) 273 (183) 0.443
Mean annual costs for non-allergic-drugs before intervention onset ineuro [mean (SD)] 33 (54) 48 (99) 0.974
Mean total annual drug costs before intervention onset in euro [mean(SD)] 349 (192) 322 (209) 0.627